Vildagliptin in New Onset Diabetes After Transplantation
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether monotherapy with Vildagliptin improve
glycemic control in kidney transplanted patients with newly diagnosed New Onset Diabetes
after Transplantation (NODAT).